Phase II study of VELCADE in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regime
- Conditions
- treatment of extranodal marginal zone B-cell non Hodgkin lymphoma of MALT type with bortezomibMedDRA version: 14.1Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2004-004594-29-IT
- Lead Sponsor
- INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Are the trial subjects under 18? yes
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method